Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease

Atherosclerosis

Volumn 194, Issue 2, 2007, Pages

  Sugiyama, Seigo ^a   Fukushima, Hironobu ^a   Kugiyama, Kiyotaka ^b   Maruyoshi, Hidetomo ^a   Kojima, Sunao ^a   Funahashi, Tohru ^c   Sakamoto, Tomohiro ^a   Horibata, Yoko ^a   Watanabe, Keisuke ^a   Koga, Hidenobu ^a   Sugamura, Koichi ^a   Otsuka, Fumiyuki ^a   Shimomura, Iichirou ^c   Ogawa, Hisao ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Adiponectin; Coronary artery disease; Diabetes mellitus; Glucose tolerance; Impaired glucose tolerance; Statin

Indexed keywords

ADIPONECTIN; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MECHANISM; FEMALE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; MALE; ORAL GLUCOSE TOLERANCE TEST; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADIPONECTIN; AGED; BLOOD GLUCOSE; CORONARY ARTERY DISEASE; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERGLYCEMIA; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; PRAVASTATIN;

EID: 34548500220     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.08.023     Document Type: Article

References (30)

1. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 (1995) 1301-1307
2. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
3. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial-lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
4. Freeman D.J., Norrie J., Sattar N., et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103 (2001) 357-362
5. Sabatine M., Wiviott S., Morrow D., McCabe C., Cannon C., and Group T.S. High-dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 substudy. Circulation 110 (2004) III-834
6. DECODE Study Group, on behalf of the European Diabetes Epidemiology Study Group. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. BMJ 1998;317:371-5.
7. American Diabetes Association and National Institute of Diabetes, Digestive and Kidney Diseases. The prevention or delay of type 2 diabetes. Diab Care 2002;25:742-9.
8. Matsuzawa Y., Funahashi T., Kihara S., and Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24 (2004) 29-33
9. Hotta K., Funahashi T., Arita Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20 (2000) 1595-1599
10. Pischon T., Girman C.J., Hotamisligil G.S., et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 (2004) 1730-1737
11. Goldfine A.B., and Kahn C.R. Adiponectin: linking the fat cell to insulin sensitivity. Lancet 362 (2003) 1431-1432
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive summary of the third report of the national cholesterol education program (NCEP) JAMA 2001;285:2486-97.
13. Matsuda M., and DeFronzo R.A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diab Care 22 (1999) 1462-1470
14. Arita Y., Kihara S., Ouchi N., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 (1999) 79-83
15. Meier U., and Gressner A.M. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 50 (2004) 1511-1525
16. Rosenson R.S., Tangney C.C., and Casey L.C. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 353 (1999) 983-984
17. Egashira K., Hirooka Y., Kai H., et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 89 (1994) 2519-2524
18. Spranger J., Kroke A., Mohlig M., et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 361 (2003) 226-228
19. Shetty G.K., Economides P.A., Horton E.S., Mantzoros C.S., and Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diab Care 27 (2004) 2450-2457
20. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 110 (2004) 3687-3692
21. Koga T., Fukuda K., Shimada Y., et al. Tissue selectivity of pravastatin sodium, lovastatin and simvastatin. The relationship between inhibition of de novo sterol synthesis and active drug concentrations in the liver, spleen and testis in rat. Eur J Biochem 209 (1992) 315-319
22. Reaven G.M. Pathophysiology of insulin resistance in human disease. Physiol Rev 75 (1995) 473-486
23. Guclu F., Ozmen B., Hekimsoy Z., and Kirmaz C. Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomed Pharmacother 58 (2004) 614-618
24. Yu Y., Ohmori K., Chen Y., et al. Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model. J Am Coll Cardiol 44 (2004) 904-913
25. Geluk C.A., Asselbergs F.W., Hillege H.L., et al. Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial. Eur Heart J 26 (2005) 1314-1320
26. Yamazaki M., Suzuki H., Hanano M., et al. Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol 264 (1993) G36-G44
27. Zivna H., Zivny P., Palicka V., and Simakova E. Influence of high cholesterol diet and pravastatin sodium on the initiation of liver regeneration in rats after partial hepatectomy. Nutrition 18 (2002) 51-55
28. Rallidis L.S., Drakoulis C.K., and Parasi A.S. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 174 (2004) 193-196
29. Prisant L.M. Preventing type II diabetes mellitus. J Clin Pharmacol 44 (2004) 406-413
30. Gannage-Yared M.H., Azar R.R., Amm-Azar M., et al. Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. Metabolism 54 (2005) 947-951